Avidity Biosciences logo

Avidity Biosciences

Avidity Biosciences (formely Avidity NanoMedicines), is a biopharma company is developing a new class of therapeutics - antibody siRNA complexes (ARCsTM), which draw on the best features of antibody-drug conjugates and nucleic acid-based medicines.

Avidity is based on pioneering nanoparticle technology developed by Mark Davis, Schlinger Professor of Chemical Engineering at Caltech and was founded to advance a new class of therapeutics, antibody-siRNA complexes (ARCsTM).

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.aviditybiosciences.com
Founded2013
Disease Focus
Development Stage
STOCK CODENon Listed
Address
10975 N. Torrey Pines Rd., Suite 150,CA 92037
La Jolla
United States
Email
Contact Number
+1 858 401 7900

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/avidity-biosciences-llc” connections=”true” suffix=””]

Aviditys proprietary ARC_ platform creates self-assembling, polymeric nanoparticles that encapsulate one or more siRNA and are decorated with monoclonal antibodies for cell-specific binding and internalization. ARCs_ overcome the cell delivery barrier that has historically limited siRNAs. ARCs_ have been optimized for in vivo delivery of siRNAs to solid tumors.

Avidity plans to advance independent programs through clinical proof-of-concept utilizing proceeds from collaborations in addition to venture financing.

Avidity currently has a strategic collaboration with a top 10 pharmaceutical company and seeks to create exceptional collaborations around specific ARC_ products in cancer and other serious diseases.

In Jan 2017, Avidity raised $16 Mn in Series B financing, with investment of $10 Mn in new capital and conversion of $6 Mn in convertible debt. Takeda Pharmaceuticals, through its venture group, led the Series B round, other investors includes Alethea Capital, Alexandria Real Estate Equities, Brace Pharma, EcoR1 Capital, F-Prime Capital, Moore Venture Partners and Tavistock Life Sciences.

In 2013, Avidity was awarded a Phase I SBIR grant and in 2014, the company raises approx $15 Mn USD Series A financing co led by Alethea Capital Management, Fidelity Biosciences, Brace Pharmaceuticals, Partner Fund Management and TPG Biotech.